Browse the evidence

Weekly subcutaneous semaglutide (up to 1 mg) as an adjunct to automated insulin delivery significantly improves glycemic control (increasing time in range by 4.8 percentage points) and reduces body weight in adults with type 1 diabetes without increasing hypoglycemia risk.

If you have Type 1 Diabetes and use an automated insulin delivery system, adding weekly semaglutide (up to 1 mg) can significantly improve your time in range and help with weight loss without increasing the risk of low blood sugar. While gastrointestinal side effects are common, they are usually manageable, and the risk of ketosis, though present, can be mitigated with education and monitoring. This is a viable option, especially for those with higher BMI.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.

GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.

Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.

GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.

Replacing saturated fatty acids with unsaturated fatty acids (specifically cis-PUFAs or cis-MUFAs) significantly decreases total cholesterol and LDL cholesterol levels.

To lower LDL cholesterol, replace saturated fats with unsaturated fats. Substituting just 1% of your daily energy from saturated fat with polyunsaturated fat (like oils from nuts/seeds/fish) can lower LDL by ~2 mg/dl.

GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, GLP-1 receptor agonists are a proven, first-line treatment option that effectively lowers blood sugar and aids weight loss. Discuss these options with your healthcare provider to see if they are appropriate for your specific health profile.

GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.

For significant weight loss, GLP-1 RAs like semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) are highly effective, producing 15% or more body weight loss in clinical trials. They work by reducing appetite and slowing digestion. While side effects like nausea are common, they often improve over time. These drugs are most effective when combined with lifestyle changes.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.

GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).

If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.

Semaglutide significantly reduces all-cause mortality and myocardial infarction risk in patients at increased risk of cardiovascular events, with high-certainty evidence.

If you are at high risk for heart issues, semaglutide is a proven treatment that lowers your risk of dying or having a heart attack. While you may experience stomach upset, these side effects are generally not serious and are outweighed by the life-saving benefits. Consult your doctor to see if this medication is appropriate for your specific risk profile.

Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.

Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.

For patients with Class I obesity (BMI 30–34.9 kg/m2), newer obesity management medications (OMM) such as tirzepatide and semaglutide provide total body weight loss (TBWL) efficacy equivalent to major metabolic bariatric surgeries (MBS) like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB), while offering superior safety and tolerability profiles.

If you have Class I obesity (BMI 30-34.9), you no longer need to choose between surgery and medication as your first step. Newer medications like tirzepatide and semaglutide can help you lose as much weight as major surgeries like gastric bypass, but with fewer risks and side effects. This makes medication a highly effective and safer first-line treatment for this specific group.

GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control primarily through delayed gastric emptying, reduced appetite, and central nervous system-mediated satiety pathways.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control, working by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize stomach upset, and increase gradually as tolerated. Expect significant weight loss (up to 20% in some trials) and improved glucose levels, but be prepared for potential gastrointestinal side effects like nausea.

Targeting specific neural circuits in the brainstem and hypothalamus using peptide-based pharmacotherapies (e.g., GLP-1 mimics) is an effective strategy for inducing weight loss and treating obesity.

Consult a healthcare provider about GLP-1 based treatments if lifestyle changes alone are insufficient. These medications work by targeting brain circuits to reduce appetite and increase satiety, offering a biologically targeted approach to weight loss.

Semaglutide (2.4 mg/week) improves physical function and reduces body weight in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) can help you feel better, walk further, and lose weight. It is taken as a weekly injection, starting at a low dose to minimize side effects.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.

For individuals with obesity or type 2 diabetes, GLP-1 and GLP-1/GIP receptor agonists are highly effective treatments that promote significant weight loss and improve blood sugar control. These medications work by mimicking natural hormones to increase insulin, reduce glucagon, slow digestion, and decrease appetite. While they can cause gastrointestinal side effects like nausea, starting with a low dose and increasing it slowly helps manage these symptoms. They are particularly beneficial for those who have not achieved sufficient weight loss or cardiovascular risk reduction with lifestyle changes alone.

Excess adiposity, particularly visceral fat, is the central driver of the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome, leading to insulin resistance, inflammation, and multi-organ dysfunction.

Managing excess body fat, especially around the waist, is the most important step in preventing heart, kidney, and liver disease. Reducing visceral fat reduces inflammation and improves insulin sensitivity, protecting your organs.

GLP-1 receptor agonists (GLP-1 RAs) produce clinically meaningful weight loss of 15–20% in clinical trials, significantly exceeding the modest 3–9% loss from alternative pharmacotherapies and the partial regain seen with lifestyle interventions alone.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective pharmacological tools for weight loss, achieving 15-20% body weight reduction. They work by targeting hormonal pathways to reduce appetite and improve metabolism. While lifestyle changes (diet and exercise) are foundational, they are often insufficient alone for sustained loss. These medications are taken weekly (or daily for liraglutide) and are intended for long-term use, as stopping them typically leads to significant weight regain. They are generally recommended for individuals with a BMI of 30 or higher, or 27 or higher with related health conditions.

Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.

If you stop taking GLP-1 medications, you will likely regain most of the weight you lost, along with your previous metabolic risks. This is because obesity is a chronic condition, not a temporary state. Just as you wouldn't stop blood pressure medication, you likely need to stay on GLP-1 therapy long-term to maintain your weight loss. The goal is sustained health, not a short-term fix.

Pharmaceutical interventions such as Tirzepatide and Semaglutide reduce obesity-related inflammation by promoting weight loss and directly modulating inflammatory pathways (e.g., reducing TNF-α, IL-6, and hs-CRP).

If lifestyle changes are insufficient, medications like Tirzepatide or Semaglutide can significantly reduce body weight and lower inflammatory markers. These are not just 'weight loss drugs' but treatments that address the underlying inflammation of obesity. Consult a doctor to see if you are a candidate.

Adherence to a Mediterranean diet reduces pro-inflammatory cytokines (TNF-α, IL-6, CRP) and improves gut microbiota composition, leading to weight loss and reduced systemic inflammation even without caloric restriction.

Adopting a Mediterranean-style diet—rich in vegetables, fruits, whole grains, and olive oil—can reduce inflammation and promote modest weight loss, even if you don't strictly count calories. Focus on food quality and gut health.

GLP-1 receptor agonist therapies significantly reduce total cardiovascular events, major adverse cardiovascular events (MACE), and all-cause mortality in nondiabetic individuals with overweight or obesity compared to placebo.

For nondiabetic adults who are overweight or obese, using GLP-1 receptor agonist therapies (such as semaglutide, tirzepatide, or liraglutide) significantly lowers the risk of heart attacks, strokes, and death from any cause compared to placebo. This benefit exists independently of diabetes status, suggesting these drugs should be considered for cardiovascular risk reduction in this population, not just for weight loss.

Semaglutide promotes significant weight loss in individuals with obesity, both with and without type 2 diabetes.

If you have obesity, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to produce significant weight loss, often exceeding 15% of body weight, when combined with lifestyle changes.

Tirzepatide treatment significantly improves health-related quality of life (HRQoL) across physical, mental, and psychosocial domains in adults with obesity or overweight, with improvements generally scaling with the magnitude of weight loss.

If you have obesity or overweight and have struggled to lose weight through lifestyle changes alone, adding tirzepatide (after achieving initial loss via diet/exercise) can significantly boost your quality of life. This isn't just about weight; it's about better physical function, less pain, and improved mental health. The more weight you lose, the more your quality of life improves, especially if you had physical limitations before starting.